News
JAGX
1.003
-4.48%
-0.047
Jaguar Health announces FDA approval of renewal of Canalevia-CA1
TipRanks · 1d ago
Jaguar Health to present crofelemer results at SABCS
TipRanks · 3d ago
Weekly Report: what happened at JAGX last week (1028-1101)?
Weekly Report · 3d ago
Weekly Report: what happened at JAGX last week (1021-1025)?
Weekly Report · 10/28 11:51
Weekly Report: what happened at JAGX last week (1014-1018)?
Weekly Report · 10/21 11:46
Jaguar Health launches Gelclair prescription product in the U.S.
TipRanks · 10/16 12:46
JAGUAR HEALTH: NAPO PHARMACEUTICALS INITIATED COMMERCIAL LAUNCH OF FDA-APPROVED ORAL MUCOSITIS PRESCRIPTION PRODUCT GELCLAIR IN U.S.
Reuters · 10/16 12:37
Weekly Report: what happened at JAGX last week (1007-1011)?
Weekly Report · 10/14 12:23
Jaguar submits abstract for study of impact of diarrhea from cancer therapies
TipRanks · 10/08 13:00
Jaguar Health Submits Late-Breaking Abstract For Study On Impact Of Diarrhea From Cancer Therapies In Breast Cancer Patients Receiving Placebo During OnTarget Phase 3 Trial
Benzinga · 10/08 12:35
Weekly Report: what happened at JAGX last week (0930-1004)?
Weekly Report · 10/07 12:09
Jaguar Health announces completed analysis from Phase 3 OnTarget trial
TipRanks · 10/01 12:55
JAGUAR HEALTH: STATISTICALLY SIGNIFICANT IMPROVEMENT IN BREAST CANCER PATIENTS IN PHASE 3 ONTARGET TRIAL FOR CROFELEMER
Reuters · 10/01 12:48
Weekly Report: what happened at JAGX last week (0923-0927)?
Weekly Report · 09/30 12:00
Weekly Report: what happened at JAGX last week (0916-0920)?
Weekly Report · 09/23 11:59
Weekly Report: what happened at JAGX last week (0909-0913)?
Weekly Report · 09/16 11:46
Weekly Report: what happened at JAGX last week (0902-0906)?
Weekly Report · 09/09 12:00
Weekly Report: what happened at JAGX last week (0826-0830)?
Weekly Report · 09/02 12:04
Weekly Report: what happened at JAGX last week (0819-0823)?
Weekly Report · 08/26 12:01
Jaguar Health Announces New Patent Issued In Hong Kong For Napo Pharmaceuticals' Crofelemer In Treating Short Bowel Syndrome And Related Conditions
Benzinga · 08/19 14:07
More
Webull provides a variety of real-time JAGX stock news. You can receive the latest news about Jaguar Health Inc through multiple platforms. This information may help you make smarter investment decisions.
About JAGX
Jaguar Health, Inc. is a commercial-stage pharmaceuticals company. The Company is focused on developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for people and animals with gastrointestinal distress. It operates through two segments: human health and animal health. The animal health segment is focused on developing and commercializing prescription and non-prescription products for companion and production animals. The human health segment is focused on developing and commercializing of human products and the ongoing commercialization of Mytesi, which is used for the symptomatic relief of non-infectious diarrhea in adults with human immunodeficiency virus (HIV)/ acquired immunodeficiency syndrome (AIDS) on antiretroviral therapy. The Canalevia-CA1 is for the treatment of chemotherapy-induced diarrhea (CID) in dogs. Its subsidiary Napo Pharmaceuticals, Inc. focuses on developing and commercializing human prescription pharmaceuticals.